**Highlights of This Issue 2139**

**REVIEW**

**2141** Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors  
Clémentine Feneyrolles, Aurélie Spelvinhauer, Léa Guiet, Bénédicte Fauvel, Bénédicte Daydé-Cazals, Pierre Warnault, Gwénaël Chevé, and Aziz Yasri

**SMALL MOLECULE THERAPEUTICS**

**2149** Direct Inhibition of Choline Kinase by a Near-Infrared Fluorescent Carbocyanine  
Sean P. Arlauckas, Anatoliy V. Popov, and Edward J. Delikatny

**2159** Selective Release of a Cyclopamine Glucuronide Prodrug toward Stem-like Cancer Cell Inhibition in Glioblastoma  
Anaïs Balbous, Brigitte Renoux, Ulrich Cortes, Serge Milin, Karline Guillouteau, Thibaut Legigan, Pierre Rivet, Odile Boissonnade, Sébastien Martin, Caroline Triplana, Michel Wager, René Jean Bensadoun, Sébastien Papot, and Lucie Karayan-Tapon

**LARGE MOLECULE THERAPEUTICS**

**2194** EpCAM-Selective Elimination of Carcinoma Cells by a Novel MAP-Based Cytolytic Fusion Protein  
Dmitrij Hristodorov, Manal Amoury, Radoslav Mladenov, Judith Niesen, Katharina Arens, Nina Berges, Lea Heim, Stefano Di Fiore, Anh-Tuan Pham, Michael Huhn, Wijnand Helfrich, Rainer Fischer, Theo Thepen, and Stefan Barth

**CANCER BIOLOGY AND SIGNAL TRANSDUCTION**

**2203** Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer  
Josephine Kam Tai Dermawan, Katerina Gurova, John Pink, Afshin Dowlati, Sarmishtha De, Goutham Narla, Neelesh Sharma, and George R. Stark

**COMPANION DIAGNOSTICS AND CANCER BIOMARKERS**

**2215** Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro  
Naoki Mine, Sayaka Yamamoto, Donald W. Kufe, Daniel D. Von Hoff, and Takumi Kawabe

**2226** Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy  
Ana Custodio, Juan Moreno-Rubio, Jorge Aparicio, Javier Gallego-Plazas, Ricardo Yaya, Joan Maurel, Nuria Rodríguez-Salas, Emilio Burgos, David Ramos, Ana Calatrava, Encarna Andrad, Esther Díaz-López, Antonio Sánchez, Rosario Madero, Paloma Cejas, and Jaime Feliu

**2238** Epidermal Growth Factor–like Domain 7 Predicts Response to First-Line Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer  
Torben Frostrup Hansen, Boje Schnack Nielsen, Flemming Brandt Sørensen, Anders Johnsson, and Anders Jakobsen
CORRECTIONS

2246 Correction: Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models

2248 Correction: Driven to Death: Inhibition of Farnesylation Increases Ras Activity in Osteosarcoma and Promotes Growth Arrest and Cell Death

ABOUT THE COVER

To elucidate the potential mode of action of MAP-based cytolytic fusion proteins in living cells, colocalization assays were performed using EGFR⁺ A549 cells transfected with a SNAP-tagged tubulin DNA construct. Expressed SNAP-tagged tubulin molecules were labeled with SNAP-Cell TMR-Star (green). EGF-MAPf151 was used as a representative for MAP-based CFPs. MAPf151 was detected using mouse–anti-human Tau and goat–anti-mouse Alexa Fluor 647 antibodies (red). DAPI was used to counterstain the nucleus (blue). Using confocal fluorescence microscopy and a tubulin polymerization assay, it could be shown that MAP colocalized with and stabilized microtubules. For more details, see article by Hristodorov and colleagues on page 2194.